Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity
Neutrophil to Lymphocyte ratio (NLR) is a critical biomarker of health of astronauts during space mission, and that of aging related illnesses, inflammaging, longevity and cancer prognosis. Oral consumption of AFO-202 strain of Aureobasidium pullulans produced Nichi BRITE and N-163 strain produced Neu REFIX together in pre-clinical and clinical studies having safely and beneficially modified NLR, are considered holding potential to help maintain astronauts health during space flight and also to bridge the gap between health span and life span by ‘Me-Byo’ phenomenon as published in Frontiers in Immunology while Neu REFIX standalone yielding enhanced dystrophin, an additional benefit that might help prevent muscle loss during space missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316966059/en/
Astronauts during space missions, deep-sea researchers, high-altitude climbers, and workers exposed to radiation hazards, are highly prone to hastened process of aging and inflammaging, reflected by increase in NLR, Interleukin-6, gut dysbiosis and immune dysfunction. Going by earlier pre-clinical & clinical studies where oral consumption of Nichi BRITE and Neu REFIX beta-glucans have shown to safely and beneficially modify those biomarkers including reduction of D-Dimer and Ferritin, besides Neu REFIX standalone reducing skeletal muscle fibrosis are considered holding potentials for benefitting those undertaking expeditions in hostile conditions. Upon validation, they could be included in the guidelines as an ingredient especially for space foods. These exo-polysaccharide beta glucans produced by unique strains of Aureobasidium Pullulans are food supplements and not a drug or remedy for any illness. Research outcomes are not to be construed as medical advice.
Astronauts during space travel are exposed to ionizing radiation, circadian rhythm disruption and microgravity leading to stress, inflammation and immune dysfunction which reflects as an increase in NLR. There has been no safe intervention using a food supplement reported yet beneficially modifying NLR, according to the authors. They added that Nichi BRITE reporting immune enhancement and anti-cancer effects, Neu REFIX for its immune modulation and anti-fibrotic effects apart from enhanced gravisensing dystrophin in pre-clinical and clinical studies; when consumed together efficiently enhances butyrate, an indicator of health and longevity through beneficial gut microbiome modulation are worth further research in simulated microgravity and for vulnerable populations, specially immunocompromised and in auto-immune diseases. These potentials may bridge the gap between health span and lifespan. Neu REFIX has been granted ODD and RPD by US FDA for treatment of Duchenne Muscular Dystrophy (DMD).
Hastening process of aging & inflammaging during space flight and muscle mass reduction similar to old age reflected by NLR and dystrophin levels, being beneficially modified by these unique exo-polysaccharide beta glucans manufactured in Japan as food supplements open a new area of research which could help space travel and also aging & longevity related health indices. Research could also be of help in the health and resilience of individuals working in harsh environmental conditions such as deep-sea researchers, high-altitude climbers, polar expeditions and workers prone to radiation hazards.
*B-1,3-1,6 glucan is a listed food additive in MHLW, Japan; Not a drug or remedy to any illness. Research findings should not be construed as medical advice. Not GRAS, EFSA certified.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250316966059/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy18.3.2025 07:00:00 CET | Press release
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases. “At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts18.3.2025 07:00:00 CET | Press release
Dr. Martin Leon to Chair the New Scientific Advisory Board (SAB) of Protembis which will also include Dr Anita Asgar, Dr Samir Kapadia and Dr Nicolas van Mieghem Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/ The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asga
Mark Wiseman appointed Chairman of Alter Domus18.3.2025 06:00:00 CET | Press release
Former Chairman of BlackRock’s Alternatives Business and Global Head of Active Equities, and President & CEO of CPPIB joins leading private markets fund servicer The appointment of Mr. Wiseman underscores Alter Domus’ position as the world’s premier global alternative asset servicer Alter Domus, the leading global provider of tech-enabled fund services for the private equity, real assets and private debt sectors today appointed Mark Wiseman as Chairman. Mr. Wiseman is the former Head of Active Equities and Chairman of BlackRock’s Alternatives Business, as well as President & CEO of Canada Pension Plan Investment Board (CPPIB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317232851/en/ Mark Wiseman Following a successful tenure, René Beltjens will step down as Chairman but will retain his seat on the Board. As alternatives specialists, with $3 trillion assets under administration (AUA), Alter Domus’ end-to-end servicing
Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse17.3.2025 23:00:00 CET | Press release
Queensland’s major airport pioneers data consolidation in the cloud to drive operational efficiency Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/ Brisbane Airport Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis. Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand. “Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to conso
Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales17.3.2025 20:37:00 CET | Press release
WLFI completes second set of WLFI governance token sales World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings. After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold. More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility. "This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom